HealthQuill Obesity
Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for medicines in the areas of diabetes and obesity.
Uncategorized

Eli Lilly to expand US facility as demand soars for diabetes, obesity medicines

Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for.

Read More
obesity
Health

Lilly’s trial results for treating obesity and pre-diabetes are promising

HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for.

Read More
The global diabetic population has risen fourfold to 828 million during the last three decades, with more than a quarter living in India, according to an analysis published in The Lancet.
Drugs Health Pharma

Global diabetic population rose fourfold to 828 million in 2022

The global diabetic population has risen fourfold to 828 million during the last three decades, with more than a quarter living in India,.

Read More
Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without worsening the condition.
Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces live scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.

Read More
Maternal deaths have risen or stagnated globally over recent years, and every two minutes, a woman dies during pregnancy or childbirth, according to the WHO.
Drugs Health Medical

Maternal eating disorder linked to increased psychiatric risks in offspring

Bharti Jayshankar October 24, 2024: In a Finnish population-based cohort study, researchers have found that mothers with a history of eating disorders or.

Read More
Denmark’s Novo Nordisk got the backing of the European Medicines Agency for its Wegovy drug to reduce heart failure in obese people.
Drugs Health Pharma

Novo’s Wegovy gets EMA nod to treat heart failure in obese people

Denmark’s Novo Nordisk got the backing of the European Medicines Agency for its Wegovy drug to reduce heart failure in obese people.

Read More
Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.
Drugs Health Pharma

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

Read More
A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the current guidelines for cholesterol and high blood pressure treatment remain the same, according to a Harvard Medical School study.
Drugs Health Pharma

New cardiovascular risk calculator may impose a burden on 16 million US citizens

HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.

Read More
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%, according to a statement from the Indianapolis-headquartered firm.
Drugs Health Pharma

Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.

Read More
The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering from heart problems or stroke.
Drugs Health Pharma

Novo Nordisk’s Wegovy gets UK regulator nod to treat heart risks

The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.

Read More